Sciex, Hepregen Team up on Metabolite Identification Offering
News May 21, 2015
Sciex and Hepregen today announced that they have signed a co-marketing agreement, under which the companies will bundle certain of their technologies together as a metabolite identification (MetID) solution for drug metabolism researchers.
The new offering centers around Hepregen's HepatoPac kit, an in vitro liver model comprising cryopreserved primary hepatocytes from a human, rat, monkey, or dog that are micropatterned onto microwell plates. It also includes Sciex's TripleTOF 6600 LC-MS system, as well as its Swath Acquisition data-capture method and MetabolitePilot software.
Specific terms of the arrangement were not disclosed.
"Until now, particularly in the case of low-turnover compounds, drug metabolism researchers have had significant difficulty predicting in vitro metabolic outcomes with complete confidence," Joe Fox, senior director of Sciex's pharma business, said in a statement. "Together with Hepregen, we have established this much needed end-to-end solution for our MetID customers."
We’ve all heard the expression: “what doesn’t kill you makes you stronger.” Now, research suggests why, at a cellular level, this might be true. Brief exposures to stressors can be beneficial by prompting the cell to trigger sustained production of antioxidants, molecules that help get rid of toxic cellular buildup related to normal metabolism.